The clinical effects of levosimendan are not attenuated by sulfonylureas

References

• Follath F. Newer treatments for decompensated heart failure: focus on levosimendan. Drug Des Devel Ther. 2009;3: 73–8.
   PubMed Web of Science ®Google Scholar
• Usta C, Eksert B, Gölbasi I, Bigat Z, Ozdem S. The role of potassium channels in the vasodilatory effect of levosimendan in human internal thoracic arteries. Eur J Cardiothorac Surg. 2006;30:329–32.
   PubMed Web of Science ®Google Scholar
• Höhn J, Pataricza J, Petri A, Tóth GK, Balogh A, Varró A, Papp JG. Levosimendan interacts with potassium channel blockers in human saphenous veins. Basic Clin Pharmacol Toxicol. 2004;94:271–3.
   PubMed Web of Science ®Google Scholar
• Kaheinen P, Pollesello P, Levijoki J, Haikala H. Levosimendan increases diastolic coronary flow in isolated guinea-pig heart by opening ATP-sensitive potassium channels. J Cardiovasc Pharmacol. 2001;37:367–74.
   PubMed Web of Science ®Google Scholar
• Kersten JR, Montgomery MW, Pagel PS, Warltier DC. Levosimendan, a new positive inotropic drug, decreases myocardial infarct size via activation of K(ATP) channels. Anesth Analg. 2000;90:5–11.
   PubMed Web of Science ®Google Scholar
• Pollesello P, Papp Z. The cardioprotective effects of levosimendan: preclinical and clinical evidence. J Cardiovasc Pharmacol. 2007;50:257–63.
   PubMed Web of Science ®Google Scholar
• Murata M, Akao M, O’Rourke B, Marbán E. Mitochondrial ATP-sensitive potassium channels attenuate matrix Ca(2+) overload during simulated ischemia and reperfusion: possible mechanism of cardioprotection. Circulation. 2001;89: 891–8.
   Web of Science ®Google Scholar
• Burger AJ, Tsao L, Aronson D. Prognostic impact of diabetes mellitus in patients with acute decompensated heart failure. Am J Cardiol. 2005;95:1117–9.
   PubMed Web of Science ®Google Scholar
• Nieminen MS, Brutsaert D, Dickstein K, Drexler H, Follath F, Harjola VP, . EuroHeart Failure Survey II (EHFS II): a survey on hospitalized acute heart failure patients: description of population. Eur Heart J. 2006;27: 2725–36.
   PubMed Web of Science ®Google Scholar
• Lefer DJ, Nichols CG, Coetzee WA. Sulfonylurea receptor 1 subunits of ATP-sensitive potassium channels and myocardial ischemia/reperfusion injury. Trends Cardiovasc Med. 2009;19:61–7.
   PubMed Web of Science ®Google Scholar
• Erdei N, Papp Z, Pollesello P, Edes I, Bagi Z. The levosimendan metabolite OR-1896 elicits vasodilation by activating the K(ATP) and BK(Ca) channels in rat isolated arterioles. Br J Pharmacol. 2006;148:696–702.
   PubMed Web of Science ®Google Scholar
• Nieminen MS, Akkila J, Hasenfuss G, Kleber FX, Lehtonen LA, Mitrovic V, . Hemodynamic and neurohumoral effects of continuous infusion of levosimendan in patients with congestive heart failure. J Am Coll Cardiol. 2000;36:1903–12.
   PubMed Web of Science ®Google Scholar
• Slawsky MT, Colucci WS, Gottlieb SS, Greenberg BH, Haeusslein E, Hare J, . Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Study investigators. Circulation. 2000;102:2222–7.
   PubMed Web of Science ®Google Scholar
• Kivikko M, Lehtonen L, Colucci WS. Sustained hemodynamic effects of intravenous levosimendan. Circulation. 2003;107:81–6
   PubMed Web of Science ®Google Scholar
• Follath F, Cleland JG, Just H, Papp JG, Scholz H, Peuhkurinen K, . Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet. 2002;360:196–202.
   PubMed Web of Science ®Google Scholar
• Moiseyev VS, Põder P, Andrejevs N, Ruda MY, Golikov AP, Lazebnik LB, . Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomized, placebo-controlled, double-blind study (RUSSLAN). Eur Heart J. 2002;23:1422–32.
   Google Scholar
• Mebazaa A, Nieminen MS, Packer M, Cohen-Solal A, Kleber FX, Pocock SJ, . Levosimendan vs Dobutamine for patients with acute decompensated heart failure: the SURVIVE randomized trial. JAMA. 2007;297:1883–91.
   PubMed Web of Science ®Google Scholar
• de Lissovoy G, Fraeman K, Teerlink JR, Mullahy J, Salon J, Sterz R, . Hospital costs for treatment of acute heart failure: economic analysis of the REVIVE II study. Eur J Health Econ. 2010;11:185–93.
   PubMed Web of Science ®Google Scholar
• From AM, Leibson CL, Bursi F, Redfield MM, Weston SA, Jacobsen SJ, . Diabetes in heart failure: prevalence and impact on outcome in the population. Am J Med. 2006; 119:591–9.
   PubMed Web of Science ®Google Scholar
• Fisman EZ, Tenenbaum A. A cardiologic approach to non-insulin antidiabetic pharmacotherapy in patients with heart disease. Cardiovasc Diabetol. 2009;8:38: doi:10.1186/1475-2840-8-38
   PubMedGoogle Scholar
• Andersson C, Olesen JB, Hansen PR, Weeke P, Norgaard ML, Jørgensen CH, . Metformin treatment is associated with a low risk of mortality in diabetic patients with heart failure: a retrospective nationwide cohort study. Diabetologia. 2010;53:2546–53.
   PubMed Web of Science ®Google Scholar
• Sandell EP, Hayha M, Antila S, Heikkinen P, Ottoila P, Lehtonen LA, Pentikainen PJ. Pharmacokinetics of levosimendan in healthy volunteers and patients with congestive heart failure. J Cardiovasc Pharmacol. 1995;26:S57–62.
   Web of Science ®Google Scholar
• Kivikko M, Antila S, Eha J, Lehtonen L, Pentikäinen PJ. Pharmacokinetics of levosimendan and its metabolites during and after a 24-hour continuous infusion in patients with severe heart failure. Int J Clin Pharmacol Ther. 2002;40:465–71.
   PubMed Web of Science ®Google Scholar
• Lilleberg J, Laine M, Palkama T, Kivikko M, Pohjanjousi P, Kupari M. Duration of the haemodynamic action of a 24-h infusion of levosimendan in patients with congestive heart failure. Eur J Heart Fail. 2007;9:75–82.
   PubMed Web of Science ®Google Scholar
• Bergh CH, Andersson B, Dahlström U, Forfang K, Kivikko M, Sarapohja T, . Intravenous levosimendan vs. dobutamine in acute decompensated heart failure patients on beta-blockers. Eur J Heart Fail. 2010;12: 404–10.
   PubMed Web of Science ®Google Scholar
• Szilágyi S, Pollesello P, Levijoki J, Kaheinen P, Haikala H, Edes I, Papp Z. The effects of levosimendan and OR-1896 on isolated hearts, myocyte-sized preparations and phosphodiesterase enzymes of the guinea pig. Eur J Pharmacol. 2004;486:67–74.
   PubMed Web of Science ®Google Scholar
• Landoni G, Biondi-Zoccai G, Greco M, Greco T, Bignami E, Morelli A, . Effects of levosimendan on mortality and hospitalization. A meta-analysis of randomized controlled studies. Crit Care Med. 2012;40:634–46.
   PubMed Web of Science ®Google Scholar
• Aguilar RB. Evaluating treatment algorithms for the management of patients with type 2 diabetes mellitus: a perspective on the definition of treatment success. Clin Ther. 2011;33:408–24.
   PubMed Web of Science ®Google Scholar